JP2010530403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530403A5 JP2010530403A5 JP2010512761A JP2010512761A JP2010530403A5 JP 2010530403 A5 JP2010530403 A5 JP 2010530403A5 JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010530403 A5 JP2010530403 A5 JP 2010530403A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- carboaryl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 230000001225 therapeutic effect Effects 0.000 claims 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 13
- 125000001931 aliphatic group Chemical group 0.000 claims 13
- 125000005488 carboaryl group Chemical group 0.000 claims 13
- 208000010877 cognitive disease Diseases 0.000 claims 7
- 208000027061 mild cognitive impairment Diseases 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- -1 diaminophenothiazine compound Chemical class 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037149 energy metabolism Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94500607P | 2007-06-19 | 2007-06-19 | |
| US60/945,006 | 2007-06-19 | ||
| PCT/GB2008/002066 WO2008155533A2 (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530403A JP2010530403A (ja) | 2010-09-09 |
| JP2010530403A5 true JP2010530403A5 (enExample) | 2011-08-04 |
| JP5725605B2 JP5725605B2 (ja) | 2015-05-27 |
Family
ID=39943003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512761A Active JP5725605B2 (ja) | 2007-06-19 | 2008-06-17 | 軽度認知障害を処置するためのフェノチアジン化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9211294B2 (enExample) |
| EP (1) | EP2167095B1 (enExample) |
| JP (1) | JP5725605B2 (enExample) |
| CN (1) | CN101820884B (enExample) |
| AU (1) | AU2008265045B2 (enExample) |
| BR (1) | BRPI0813670A2 (enExample) |
| CA (1) | CA2690746C (enExample) |
| DK (1) | DK2167095T3 (enExample) |
| ES (1) | ES2739546T3 (enExample) |
| HR (1) | HRP20191513T1 (enExample) |
| HU (1) | HUE045460T2 (enExample) |
| MY (1) | MY177001A (enExample) |
| PL (1) | PL2167095T3 (enExample) |
| PT (1) | PT2167095T (enExample) |
| SI (1) | SI2167095T1 (enExample) |
| WO (1) | WO2008155533A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| EP2205245B1 (en) * | 2007-10-03 | 2015-06-24 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| US8785434B2 (en) | 2010-04-30 | 2014-07-22 | Prosetta Antiviral Inc. | Antiviral compounds |
| PT2673266T (pt) * | 2011-02-11 | 2016-10-07 | Wista Lab Ltd | Sais de fenotiazina diamínio e sua utilização |
| EP2951149B1 (en) * | 2013-01-30 | 2018-10-10 | Ecolab USA Inc. | Hydrogen sulfide scavengers |
| US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
| WO2016133995A1 (en) | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| MX385594B (es) | 2016-07-25 | 2025-03-18 | Wista Lab Ltd | Administracion y dosificacion de diaminofenotiazinas. |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| US12280061B2 (en) * | 2018-07-26 | 2025-04-22 | Wista Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| EP4676489A1 (en) | 2023-03-03 | 2026-01-14 | TauRx Therapeutics Management Ltd. | Diaminophenothiazine for the treatment of microvascular brain disease disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| US20070037848A1 (en) * | 2003-04-03 | 2007-02-15 | Masters Colin L | Treatment of neurological conditions |
| ES2736160T3 (es) * | 2004-09-23 | 2019-12-26 | Wista Lab Ltd | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| JP5186212B2 (ja) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| WO2007110629A1 (en) * | 2006-03-29 | 2007-10-04 | Wista Laboratories Ltd | Inhibitors of protein aggregation |
| CN103641794B (zh) | 2006-03-29 | 2016-09-21 | 维斯塔实验室有限公司 | 锍化合物及其用途 |
| ES2349322T7 (es) * | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| PT2457905T (pt) * | 2006-07-11 | 2016-11-24 | Wista Lab Ltd | Processos de síntese e/ou purificação de compostos diaminofenotiazínio |
-
2008
- 2008-06-17 PT PT08762390T patent/PT2167095T/pt unknown
- 2008-06-17 CN CN2008801031955A patent/CN101820884B/zh active Active
- 2008-06-17 PL PL08762390T patent/PL2167095T3/pl unknown
- 2008-06-17 HR HRP20191513 patent/HRP20191513T1/hr unknown
- 2008-06-17 BR BRPI0813670-0A2A patent/BRPI0813670A2/pt not_active Application Discontinuation
- 2008-06-17 JP JP2010512761A patent/JP5725605B2/ja active Active
- 2008-06-17 US US12/665,608 patent/US9211294B2/en active Active
- 2008-06-17 DK DK08762390.6T patent/DK2167095T3/da active
- 2008-06-17 WO PCT/GB2008/002066 patent/WO2008155533A2/en not_active Ceased
- 2008-06-17 SI SI200832080T patent/SI2167095T1/sl unknown
- 2008-06-17 HU HUE08762390A patent/HUE045460T2/hu unknown
- 2008-06-17 ES ES08762390T patent/ES2739546T3/es active Active
- 2008-06-17 CA CA2690746A patent/CA2690746C/en active Active
- 2008-06-17 AU AU2008265045A patent/AU2008265045B2/en active Active
- 2008-06-17 MY MYPI20095255A patent/MY177001A/en unknown
- 2008-06-17 EP EP08762390.6A patent/EP2167095B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530403A5 (enExample) | ||
| JP2009531404A5 (enExample) | ||
| JP7407740B2 (ja) | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 | |
| JP2019104748A5 (enExample) | ||
| AU2012274160B2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| JP2012507522A5 (enExample) | ||
| ES2773543T3 (es) | Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4 | |
| TW200529850A (en) | Methods of preparing aripiprazole crystalline forms | |
| JP2009528271A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP6830888B2 (ja) | Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法 | |
| JP2014511898A5 (enExample) | ||
| JP2010155827A5 (enExample) | ||
| JP2009506014A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| AU2015335783A1 (en) | Tricyclic atropisomer compounds | |
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| ES2907590T3 (es) | Método para preparar un derivado heterocíclico | |
| JP6129471B2 (ja) | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の製造方法 | |
| CN1791595A (zh) | 溴化物及其晶体 | |
| JP2007538031A5 (enExample) | ||
| JP5710490B2 (ja) | （ｒ）−５−（（ｅ）−２−（ピロリジン−３−イルビニル）ピリミジンの合成および新規の塩形態 | |
| JP2018529643A (ja) | ユビキチン化−プロテアソーム系に関連する化合物および薬学的組成物 | |
| TW201018668A (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives | |
| JP2009525292A5 (enExample) |